The global pomalidomide market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing number of patients suffering from myelodysplastic syndromes and acute myeloid leukemia. The increasing prevalence of these diseases is also driving the growth of this market.
The global pomalidomide market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into 1mg tables, 2mg tables, and 4mg tables; on the basis of application it is segmented into hospital, drug center or clinic; and on the basis of region it is segmented into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA).
Some Of The Growth Factors Of This Market:
- The drug is used to treat multiple myeloma, a type of cancer that affects the bone marrow and blood cells.
- It is also used to treat other types of cancer such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.
- The drug has been approved by the FDA for use in patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (e.g., lenalidomide).
- Pomalidomide was developed by Celgene Corporation.
- Pomalidomide is marketed under the trade name Pomalyst.
Industry Growth Insights published a new data on “Pomalidomide Market”. The research report is titled “Pomalidomide Market research by Types (1mg Tables, 2mg Tables, 4mg Tables), By Applications (Hospital, Drug Center, Clinic, Other), By Players/Companies Celgene, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, SL PHARM”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pomalidomide Market Research Report
By Type
1mg Tables, 2mg Tables, 4mg Tables
By Application
Hospital, Drug Center, Clinic, Other
By Companies
Celgene, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, SL PHARM
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Pomalidomide Market Report Segments:
The global Pomalidomide market is segmented on the basis of:
Types
1mg Tables, 2mg Tables, 4mg Tables
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Center, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- SL PHARM
Highlights of The Pomalidomide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1mg Tables
- 2mg Tables
- 4mg Tables
- By Application:
- Hospital
- Drug Center
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pomalidomide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pomalidomide is a medication used to treat multiple myeloma. It works by slowing the growth of cancer cells in the bone marrow.
Some of the major players in the pomalidomide market are Celgene, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, SL PHARM.
The pomalidomide market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pomalidomide Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pomalidomide Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pomalidomide Market - Supply Chain
4.5. Global Pomalidomide Market Forecast
4.5.1. Pomalidomide Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pomalidomide Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pomalidomide Market Absolute $ Opportunity
5. Global Pomalidomide Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pomalidomide Market Size and Volume Forecast by Type
5.3.1. 1mg Tables
5.3.2. 2mg Tables
5.3.3. 4mg Tables
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pomalidomide Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pomalidomide Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Drug Center
6.3.3. Clinic
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pomalidomide Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pomalidomide Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pomalidomide Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pomalidomide Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pomalidomide Demand Share Forecast, 2019-2026
9. North America Pomalidomide Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pomalidomide Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pomalidomide Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Drug Center
9.4.3. Clinic
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pomalidomide Market Size and Volume Forecast by Type
9.7.1. 1mg Tables
9.7.2. 2mg Tables
9.7.3. 4mg Tables
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pomalidomide Demand Share Forecast, 2019-2026
10. Latin America Pomalidomide Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pomalidomide Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pomalidomide Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Drug Center
10.4.3. Clinic
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pomalidomide Market Size and Volume Forecast by Type
10.7.1. 1mg Tables
10.7.2. 2mg Tables
10.7.3. 4mg Tables
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pomalidomide Demand Share Forecast, 2019-2026
11. Europe Pomalidomide Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pomalidomide Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pomalidomide Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Drug Center
11.4.3. Clinic
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pomalidomide Market Size and Volume Forecast by Type
11.7.1. 1mg Tables
11.7.2. 2mg Tables
11.7.3. 4mg Tables
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
1110.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pomalidomide Demand Share, 2019-2026
12. Asia Pacific Pomalidomide Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pomalidomide Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pomalidomide Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Drug Center
12.4.3. Clinic
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pomalidomide Market Size and Volume Forecast by Type
12.7.1. 1mg Tables
12.7.2. 2mg Tables
12.7.3. 4mg Tables
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pomalidomide Demand Share, 2019-2026
13. Middle East & Africa Pomalidomide Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pomalidomide Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pomalidomide Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Drug Center
13.4.3. Clinic
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pomalidomide Market Size and Volume Forecast by Type
13.7.1. 1mg Tables
13.7.2. 2mg Tables
13.7.3. 4mg Tables
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pomalidomide Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pomalidomide Market: Market Share Analysis
14.2. Pomalidomide Distributors and Customers
14.3. Pomalidomide Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Celgene
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Natco Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Intas Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Indiabulls Pharmaceutical
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cipla
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Glenmark Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dr Reddy's Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Qilu Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Chia Tai-Tianqing
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hanson Pharm
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Meidakang Huakang Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Shandong Kongfu Pharmaceutical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. SL PHARM
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
